ES2551315T3 - Composiciones de fenilalanina amoníaco-liasa procariótica y métodos de uso de dichas composiciones - Google Patents
Composiciones de fenilalanina amoníaco-liasa procariótica y métodos de uso de dichas composiciones Download PDFInfo
- Publication number
- ES2551315T3 ES2551315T3 ES08754717.0T ES08754717T ES2551315T3 ES 2551315 T3 ES2551315 T3 ES 2551315T3 ES 08754717 T ES08754717 T ES 08754717T ES 2551315 T3 ES2551315 T3 ES 2551315T3
- Authority
- ES
- Spain
- Prior art keywords
- avpal
- pal
- peg
- protein
- fifty
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/51—Lyases (4)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/88—Lyases (4.)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Obesity (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US807227 | 1991-12-16 | ||
| US11/807,227 US7534595B2 (en) | 2006-06-12 | 2007-05-25 | Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof |
| PCT/US2008/006661 WO2008153776A1 (en) | 2007-05-25 | 2008-05-23 | Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using said compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2551315T3 true ES2551315T3 (es) | 2015-11-18 |
Family
ID=39868905
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES08754717.0T Active ES2551315T3 (es) | 2007-05-25 | 2008-05-23 | Composiciones de fenilalanina amoníaco-liasa procariótica y métodos de uso de dichas composiciones |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US7534595B2 (enExample) |
| EP (2) | EP2152868B1 (enExample) |
| JP (1) | JP5670183B2 (enExample) |
| KR (2) | KR101603796B1 (enExample) |
| CN (1) | CN101842482B (enExample) |
| AR (2) | AR066716A1 (enExample) |
| AU (1) | AU2008263190B2 (enExample) |
| BR (1) | BRPI0811267B8 (enExample) |
| CA (1) | CA2687450C (enExample) |
| CL (1) | CL2008001497A1 (enExample) |
| CY (2) | CY1116894T1 (enExample) |
| DK (1) | DK2152868T3 (enExample) |
| EA (1) | EA018443B1 (enExample) |
| ES (1) | ES2551315T3 (enExample) |
| HR (1) | HRP20151268T1 (enExample) |
| HU (2) | HUE025784T2 (enExample) |
| IL (1) | IL202132A (enExample) |
| LT (1) | LTC2152868I2 (enExample) |
| LU (1) | LUC00133I2 (enExample) |
| MX (1) | MX2009012453A (enExample) |
| MY (1) | MY151413A (enExample) |
| NL (1) | NL301011I2 (enExample) |
| NO (1) | NO2019037I1 (enExample) |
| PE (1) | PE20090315A1 (enExample) |
| PL (1) | PL2152868T3 (enExample) |
| PT (1) | PT2152868E (enExample) |
| SI (1) | SI2152868T1 (enExample) |
| TW (1) | TWI418633B (enExample) |
| WO (1) | WO2008153776A1 (enExample) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7534595B2 (en) | 2006-06-12 | 2009-05-19 | Biomarin Pharmaceutical Inc. | Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof |
| US7531341B1 (en) | 2006-06-12 | 2009-05-12 | Biomarin Pharmaceutical Inc. | Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof |
| US7537923B2 (en) * | 2007-08-17 | 2009-05-26 | Biomarin Pharmaceutical Inc. | Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating cancer using compositions thereof |
| WO2010014225A2 (en) * | 2008-07-30 | 2010-02-04 | Biomarin Pharmaceutical Inc. | Assays for detection of phenylalanine ammonia-lyase and antibodies to phenylalanine ammonia-lyase |
| EP4062928A3 (en) | 2010-02-04 | 2022-11-30 | BioMarin Pharmaceutical Inc. | Prokaryotic phenylalanine ammonia-lyases and their use for treating phenylketonuria and hyperphenylalaninemia |
| EP3222288A1 (en) * | 2012-07-27 | 2017-09-27 | University of North Texas | Genetically modified probiotic for the treatment of phenylketonuria (pku) disease |
| PL2986722T3 (pl) | 2013-04-18 | 2019-10-31 | Codexis Inc | Skonstruowane polipeptydy amoniakoliazy fenyloalaniny |
| BR112016011195A2 (pt) | 2013-11-18 | 2017-09-19 | Rubius Therapeutics Inc | Células eritroides enucleadas e seus métodos de fabricação, composição farmacêutica e seu uso, uso de uma população de células eritroides, biorreator, mistura de células e dispositivo médico |
| CN106456744A (zh) | 2014-04-01 | 2017-02-22 | 鲁比厄斯治疗法股份有限公司 | 用于免疫调节的方法和组合物 |
| EP3145536B1 (en) | 2014-04-16 | 2021-10-27 | Codexis, Inc. | Engineered tyrosine ammonia lyase |
| CA2970638A1 (en) | 2014-12-22 | 2016-06-30 | Codexis, Inc. | Human alpha-galactosidase variants |
| TW202440903A (zh) | 2015-08-04 | 2024-10-16 | 美商再生元醫藥公司 | 補充牛磺酸之細胞培養基及用法（一） |
| JP6994018B2 (ja) | 2016-07-26 | 2022-01-14 | バイオマリン ファーマシューティカル インコーポレイテッド | 新規アデノ随伴ウイルスキャプシドタンパク質 |
| CN109844127B (zh) * | 2016-08-30 | 2023-09-19 | 三菱化学株式会社 | 突变型酶的制造方法及突变型醇酰基转移酶 |
| CN106497905A (zh) * | 2016-12-14 | 2017-03-15 | 江南大学 | 一株鱼腥藻来源的苯丙氨酸脱氨酶的突变体 |
| AU2018217495B2 (en) * | 2017-02-13 | 2021-03-04 | Codexis, Inc. | Engineered phenylalanine ammonia lyase polypeptides |
| CN107653275A (zh) * | 2017-10-30 | 2018-02-02 | 安徽工程大学 | D‑苯丙氨酸的制备方法 |
| CN108004225B (zh) * | 2017-12-19 | 2020-05-08 | 江南大学 | 一种成团泛菌来源的苯丙氨酸氨基变位酶的突变体 |
| KR20210008501A (ko) | 2018-05-09 | 2021-01-22 | 바이오마린 파머수티컬 인크. | 페닐케톤뇨증을 치료하는 방법 |
| TW202005978A (zh) | 2018-05-14 | 2020-02-01 | 美商拜奧馬林製藥公司 | 新穎肝靶向腺相關病毒載體 |
| EP3807409A4 (en) | 2018-06-12 | 2022-08-03 | Codexis, Inc. | Engineered tyrosine ammonia lyase |
| EP3820833A4 (en) * | 2018-07-12 | 2022-08-03 | Codexis, Inc. | MODIFIED AMMONIA-LYASE PHENYLALANINE POLYPEPTIDES |
| AU2019397401A1 (en) | 2018-12-14 | 2021-06-17 | Codexis, Inc. | Engineered tyrosine ammonia lyase |
| MY207075A (en) | 2018-12-20 | 2025-01-28 | Codexis Inc | Human alpha-galactosidase variants |
| CN110456056A (zh) * | 2019-07-22 | 2019-11-15 | 浙江大学 | 一种新生儿苯丙酮尿症无创筛查试纸的制备方法 |
| BR112022003705A2 (pt) | 2019-08-30 | 2022-05-24 | Codexis Inc | Lipase recombinante, composição, sequência de polinucleotídeo recombinante, vetor de expressão, composição farmacêutica para o tratamento de insuficiência pancreática, célula hospedeira, métodos para produzir uma lipase recombinante e para tratar e/ou prevenir os sintomas de insuficiência pancreática, e, uso |
| MX2022007399A (es) | 2019-12-20 | 2022-09-19 | Codexis Inc | Variantes de alfa-glucosidasa ácida diseñadas. |
| EP4103711A4 (en) | 2020-02-04 | 2024-02-28 | Codexis, Inc. | Engineered leucine decarboxylases |
| WO2021168060A1 (en) * | 2020-02-19 | 2021-08-26 | Trustees Of Tufts College | Methods for engineering amino acid ammonia lyase enzymes and enzymes thereby obtained |
| TW202144575A (zh) | 2020-04-03 | 2021-12-01 | 美商拜奧馬林製藥公司 | 使用ａａｖ及治療調配物之苯酮尿症治療 |
| JP2023539634A (ja) | 2020-08-28 | 2023-09-15 | コデクシス， インコーポレイテッド | 操作されたアミラーゼバリアント |
| AU2021334371A1 (en) | 2020-08-28 | 2023-03-09 | Codexis, Inc. | Engineered protease variants |
| WO2022245924A1 (en) * | 2021-05-19 | 2022-11-24 | Biomarin Pharmaceutical Inc. | Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating adolescent subjects |
| AU2022279241A1 (en) | 2021-05-21 | 2023-11-30 | Syntis Bio, Inc. | Engineered methionine gamma lyase variants |
| WO2023044381A1 (en) * | 2021-09-16 | 2023-03-23 | Arcturus Therapeutics, Inc. | Compositions and methods for treating phenylketonuria |
| JP2024540358A (ja) | 2021-11-01 | 2024-10-31 | シンティス バイオ，インコーポレイティド | 工学操作ロイシン脱炭酸酵素 |
| CN117417925A (zh) * | 2022-07-18 | 2024-01-19 | 浙江泽科塔生物医药有限公司 | Pal变体、包含该pal变体的药物组合物以及用于制备该pal变体的方法 |
| CN118931888A (zh) * | 2023-05-09 | 2024-11-12 | 重庆派金生物科技有限公司 | 苯丙氨酸裂解酶突变体及其偶联物或其药学上可接受的盐 |
| GB202307239D0 (en) | 2023-05-15 | 2023-06-28 | Evox Therapeutics Ltd | Gene therapies for Phenylketonuria |
| CN116478975B (zh) * | 2023-06-16 | 2023-09-01 | 苏州优信合生技术有限公司 | 高活性苯丙氨酸解氨酶突变体及其表达菌株 |
| WO2025106759A1 (en) | 2023-11-17 | 2025-05-22 | Biomarin Pharmaceutical Inc. | Conjugates of phenylalanine ammonia-lyase and poegma and methods for their use |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4252822A (en) | 1979-12-26 | 1981-02-24 | Children's Hospital Medical Center | Method for treating phenylketonuria |
| US4562151A (en) | 1983-09-06 | 1985-12-31 | Monsanto Company | Stabilization of L-phenylalanine ammonia-lyase enzyme |
| US5206344A (en) | 1985-06-26 | 1993-04-27 | Cetus Oncology Corporation | Interleukin-2 muteins and polymer conjugation thereof |
| US5166322A (en) | 1989-04-21 | 1992-11-24 | Genetics Institute | Cysteine added variants of interleukin-3 and chemical modifications thereof |
| US5766897A (en) | 1990-06-21 | 1998-06-16 | Incyte Pharmaceuticals, Inc. | Cysteine-pegylated proteins |
| WO1994013817A1 (en) | 1992-12-04 | 1994-06-23 | Me Medical Enzymes Ag | Genetically engineered glutaminase and its use in antiviral and anticancer therapy |
| JP2930723B2 (ja) | 1992-11-19 | 1999-08-03 | アンティキャンサー インコーポレーテド | 抗メチオニン化学療法における抗腫瘍薬としてのメチオニナーゼの使用 |
| DK75593D0 (enExample) | 1993-06-25 | 1993-06-25 | Novo Nordisk As | |
| JPH09510352A (ja) * | 1994-03-15 | 1997-10-21 | プリズム ファーマシューティカルズ，インコーポレイティド | 遺伝子療法及び前部の眼疾患のためのヘパリン結合成長因子 |
| ATE455171T1 (de) | 1995-09-21 | 2010-01-15 | Genentech Inc | Varianten des menschlichen wachstumshormons |
| CU22585A1 (es) * | 1995-11-17 | 1999-11-03 | Centro Inmunologia Molecular | Anticuerpos monoclonales antiidiótipos (ab2) de tipo igg con alta conectividad idiotípica y composiciones farmacéuticas que los contienen. su uso como inmunoreguladores de la respuesta inmune. |
| US6548644B1 (en) | 1997-03-10 | 2003-04-15 | Immunex Corporation | Site protected protein modification |
| US6183738B1 (en) | 1997-05-12 | 2001-02-06 | Phoenix Pharamacologics, Inc. | Modified arginine deiminase |
| US5981239A (en) | 1997-09-24 | 1999-11-09 | Great Lakes Chemical Corp. | Synthesis of optically active phenylalanine analogs using Rhodotorula graminis |
| US7026446B1 (en) * | 1997-12-24 | 2006-04-11 | Diatech Pty Ltd. | Bifunctional molecules |
| TWI227241B (en) * | 1998-06-20 | 2005-02-01 | United Biomedical Inc | IgE-CH3 domain antigen peptide, peptide conjugate containing the same, and pharmaceutical composition for treating allergies containing the peptide conjugate |
| US6451986B1 (en) | 1998-06-22 | 2002-09-17 | Immunex Corporation | Site specific protein modification |
| US6461849B1 (en) | 1998-10-13 | 2002-10-08 | Novozymes, A/S | Modified polypeptide |
| US6403312B1 (en) | 1998-10-16 | 2002-06-11 | Xencor | Protein design automatic for protein libraries |
| US6686164B1 (en) | 1998-10-30 | 2004-02-03 | Novozymes A/S | Low allergenic protein variants |
| CA2328614C (en) | 1999-02-12 | 2012-06-26 | Biostream, Inc. | Matrices for drug delivery and methods for making and using the same |
| WO2001041782A2 (en) * | 1999-12-09 | 2001-06-14 | Chiron Corporation | Method for administering a cytokine to the central nervous system and the lymphatic system |
| US6586398B1 (en) | 2000-04-07 | 2003-07-01 | Amgen, Inc. | Chemically modified novel erythropoietin stimulating protein compositions and methods |
| EP1280924A2 (en) | 2000-04-14 | 2003-02-05 | University of South Carolina Research Foundation | Cloning of corynebacteriaceae histidine ammonia lyase and therapeutic uses |
| US6967097B2 (en) | 2000-07-24 | 2005-11-22 | Pcbu Services, Inc. | Phenylalainine ammonia lyase polypeptide and polynucleotide sequences and methods of obtaining and using same |
| EP1309705B1 (en) * | 2000-07-25 | 2012-02-15 | Immunomedics Inc. | Multivalent target binding protein |
| WO2002026028A2 (en) * | 2000-09-26 | 2002-04-04 | The Regents Of The University Of California | Characterization of phenylalanine ammonia-lyase (pal) gene in wounded lettuce |
| WO2002038609A2 (en) * | 2000-11-10 | 2002-05-16 | Proteopharma Aps | Apolipoprotein conjugates |
| JP4722396B2 (ja) | 2002-02-26 | 2011-07-13 | イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー | 遺伝要素の組換え方法 |
| AU2003246690B2 (en) * | 2002-07-17 | 2010-03-11 | Cytos Biotechnology Ag | Molecular antigen arrays using a virus like particle derived from the AP205 coat protein |
| JP2006516095A (ja) | 2002-11-14 | 2006-06-22 | ザ スクリップス リサーチ インスティテュート | 脂肪酸アミドヒドロラーゼ（ｆａａｈ）の結晶形 |
| AU2004247737B2 (en) * | 2003-06-11 | 2009-04-23 | Wyeth | Platelet glycoprotein IB alpha variant fusion polypeptides and methods of use thereof |
| FR2868318B1 (fr) * | 2004-04-01 | 2012-11-16 | Commissariat Energie Atomique | Antigene tat stabilise et ses applications pour la vaccination anti-vih |
| US7670595B2 (en) * | 2004-06-28 | 2010-03-02 | Merck Patent Gmbh | Fc-interferon-beta fusion proteins |
| AU2005286763A1 (en) | 2004-09-17 | 2006-03-30 | Biomarin Pharmaceutical, Inc. | Variants and chemically-modified variants of phenylalanine ammonia-lyase |
| EP1869174B1 (en) | 2005-03-10 | 2015-02-18 | BASF Enzymes LLC | Lyase enzymes, nucleic acids encoding them and methods for making and using them |
| US7534595B2 (en) * | 2006-06-12 | 2009-05-19 | Biomarin Pharmaceutical Inc. | Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof |
| WO2008069958A2 (en) | 2006-12-01 | 2008-06-12 | The Salk Institute For Biological Studies | Substrate switched ammonia lyases and mutases |
| US7537923B2 (en) | 2007-08-17 | 2009-05-26 | Biomarin Pharmaceutical Inc. | Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating cancer using compositions thereof |
-
2007
- 2007-05-25 US US11/807,227 patent/US7534595B2/en active Active
-
2008
- 2008-05-23 CL CL2008001497A patent/CL2008001497A1/es unknown
- 2008-05-23 AR ARP080102198A patent/AR066716A1/es active IP Right Grant
- 2008-05-23 JP JP2010509405A patent/JP5670183B2/ja active Active
- 2008-05-23 PT PT87547170T patent/PT2152868E/pt unknown
- 2008-05-23 BR BRPI0811267A patent/BRPI0811267B8/pt active IP Right Grant
- 2008-05-23 PE PE2008000889A patent/PE20090315A1/es active IP Right Grant
- 2008-05-23 ES ES08754717.0T patent/ES2551315T3/es active Active
- 2008-05-23 MX MX2009012453A patent/MX2009012453A/es active IP Right Grant
- 2008-05-23 EP EP08754717.0A patent/EP2152868B1/en active Active
- 2008-05-23 CA CA2687450A patent/CA2687450C/en active Active
- 2008-05-23 HU HUE08754717A patent/HUE025784T2/en unknown
- 2008-05-23 PL PL08754717T patent/PL2152868T3/pl unknown
- 2008-05-23 HR HRP20151268TT patent/HRP20151268T1/hr unknown
- 2008-05-23 DK DK08754717.0T patent/DK2152868T3/en active
- 2008-05-23 CN CN200880016898.4A patent/CN101842482B/zh active Active
- 2008-05-23 EP EP13169362.4A patent/EP2657335A1/en not_active Withdrawn
- 2008-05-23 MY MYPI20094868 patent/MY151413A/en unknown
- 2008-05-23 KR KR1020097027018A patent/KR101603796B1/ko active Active
- 2008-05-23 SI SI200831540T patent/SI2152868T1/sl unknown
- 2008-05-23 EA EA200970980A patent/EA018443B1/ru unknown
- 2008-05-23 TW TW097119178A patent/TWI418633B/zh active
- 2008-05-23 WO PCT/US2008/006661 patent/WO2008153776A1/en not_active Ceased
- 2008-05-23 KR KR20157007821A patent/KR20150038753A/ko not_active Ceased
- 2008-05-23 AU AU2008263190A patent/AU2008263190B2/en active Active
-
2009
- 2009-11-15 IL IL202132A patent/IL202132A/en active IP Right Grant
-
2015
- 2015-11-06 CY CY20151100997T patent/CY1116894T1/el unknown
-
2018
- 2018-01-17 AR ARP180100106A patent/AR110834A2/es unknown
-
2019
- 2019-10-09 NL NL301011C patent/NL301011I2/nl unknown
- 2019-10-10 LT LTPA2019517C patent/LTC2152868I2/lt unknown
- 2019-10-14 LU LU00133C patent/LUC00133I2/fr unknown
- 2019-10-16 NO NO2019037C patent/NO2019037I1/no unknown
- 2019-10-17 CY CY2019039C patent/CY2019039I2/el unknown
- 2019-10-18 HU HUS1900049C patent/HUS1900049I1/hu unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wang et al. | Structure-based chemical modification strategy for enzyme replacement treatment of phenylketonuria | |
| EP1708755B1 (en) | Transglutaminase mediated conjugation of peptides | |
| ES2729048T3 (es) | Polipéptidos de fenilalanina amoníaco-liasa modificados | |
| ES2874077T3 (es) | Métodos y compuestos mejorados para eliminar respuestas inmunitarias a agentes terapéuticos | |
| CN102119033B (zh) | 用于增强促生长素抑制素免疫原性的组合物和方法 | |
| EA018443B1 (ru) | Композиции прокариотической фенилаланин-аммиак-лиазы и способы применения указанных композиций | |
| JP2017101074A (ja) | ヒト成長ホルモン類似体を用いた小児成長ホルモン分泌不全症の治療 | |
| JP2008513027A (ja) | フェニルアラニンアンモニアーリアーゼの改変体および化学的に修飾された改変体 | |
| KR20100125290A (ko) | 유전적으로 코딩된 비천연 아미노산에 의한 면역 내성의 파괴 | |
| CN112574982A (zh) | 用于治疗高胱氨酸尿症的胱硫醚β-合酶 | |
| Agmon et al. | On ribosome conservation and evolution | |
| JP2021511308A (ja) | 改変タンパク質 | |
| Verlinde et al. | Protein crystallography and infectious diseases | |
| BR112019023800A2 (pt) | depleção mediada por enzima humana de homocisteína para tratar pacientes com hiperhomocisteinemia e homocistinúria | |
| JP2010536923A (ja) | タンパク質を選択的に修飾するための組成物と方法 | |
| JP2010536923A5 (enExample) | ||
| Aragão et al. | Structure of dimeric cytochrome c3 from Desulfovibrio gigas at 1.2 Å resolution | |
| BRPI0511793B1 (pt) | proteínas quiméricas isoladas de lumazina sintase modificada | |
| Asojo et al. | Structures of thymus and activation-regulated chemokine (TARC) | |
| Mao et al. | Crystallization and preliminary X-ray diffraction study of the farnesyl diphosphate synthase from Trypanosoma brucei | |
| Castell et al. | Structural analysis of mycobacterial branched-chain aminotransferase: implications for inhibitor design | |
| Raasakka et al. | Structure of the mouse acidic amino acid decarboxylase GADL1 | |
| Reiland et al. | Binding of inhibitory aromatic amino acids to Streptomyces griseus aminopeptidase | |
| WO2009116524A9 (ja) | 改変タンパク質 | |
| US20220275049A1 (en) | Antigenic polypeptides and methods of use thereof |